Amgen to Buy Celgene’s Otezla for $13.4 Billion

Written by Bryan Shin


August 27, 2019


The American multinational biopharmaceutical company, Amgen (NASDAQ: AMGN) agreed to buy Celgene’s (NASDAQ: CELG) Otezla, which is a psoriasis treatment, for USD 13.4 Billion.

The acquisition clears the way for Bristol-Myers Squibb to push ahead with its USD 90 Billion takeover of Celgene announced in early January. Otezla had sales of USD 1.61 Billion last year and the sales are expected to grow at least in the low-double digits over the next five years.

The focus of most of pharmaceutical groups is on becoming part of the top three players in the industry. Indeed, as Pharmaceutical and Healthcare companies own drugs are close to losing patent protection, the majority of the deals in the industry this year have been mostly driven by the will to sell non-core assets or buy innovative medicines according to the Financial Times.

So far this year, more than USD 700 Billion worth of transactions have been agreed in the pharmaceutical and healthcare sector, but Bristol-Myers’s acquisition of Celgene is the largest in the largest pharma deal.

The deal is expected to produce tax benefits of a USD 2.2 Billion present cash value for Amgen and Bristol-Myers said most of the profits from the sale will be used to pay back debt from the Celgene deal and has announced that it plans to buy back USD 7 Billion worth of shares, up from the previously planned USD 5 Billion.

Stock price


52 week low/high


Related Articles

Sanofi Acquires Synthrox for USD 2.5 Billion

Sanofi Acquires Synthrox for USD 2.5 Billion

Healthcare & Biotechs0 Comments Sanofi (NASDAQ: SNY) announced on Monday that it has acquired Synthorx (NASDAQ: THOR) for USD 2.5 Billion to boost its immuno-oncology pipeline. Synthorx shares surged by 169% at the open on Monday. Synthorx is...

Novartis to Buy The Medicines Co. for USD 9.7 Billion

Novartis to Buy The Medicines Co. for USD 9.7 Billion

Healthcare & Biotechs0 Comments Swiss pharmaceutical company Novartis AG (NYSE: NVS) on Sunday said it will buy cholesterol-drug maker The Medicines Company (NASDAQ: MDCO) for USD 9.7 Billion. Shares of The Medicines Company shot up about 22%...

Planet Fitness (NYSE: PLNT) Jumps After Sales Beat Expectations

Planet Fitness (NYSE: PLNT) Jumps After Sales Beat Expectations

Healthcare & Biotechs0 Comments Planet Fitness, Inc. (NYSE: PLNT) stock jumped about 10% after the franchisee and operator of fitness centers reported financial results for its third quarter ended September 30, 2019.  Third Quarter Fiscal...


Leave a Reply

Notify of